|Videos|May 5, 2017

How Might Contact Precautions Affect Quality of Care?

Gonzalo Bearman, MD, MPH, professor of medicine, and hospital epidemiologist, Department of Internal Medicine and Infectious Diseases, Virginia Commonwealth University, explains how contact precautions can affect a patient’s wellbeing and quality of care.

Gonzalo Bearman, MD, MPH, professor of medicine, and hospital epidemiologist, Department of Internal Medicine and Infectious Diseases, Virginia Commonwealth University, explains how contact precautions can affect a patient’s wellbeing and quality of care.

Interview Transcript (slightly modified for readability)

“Adverse events associated with contact precautions is also a controversial area, but it’s believed that patients who are isolated, or put on contact precautions, have issues with fewer doctor or nurse visits. Sometimes, [they have] greater issues with adverse consequences like electrolyte disorders, fluid imbalances, sometimes psychological impacts, such as isolation, sadness, or psychiatric or neuro-psychiatric issues related to that.

Last, but not least, there’s concern that isolating patients also has an impact on the throughput or the movement of the patient through the healthcare system. So, more people wait for room on the front end, either in the emergency department, and then at the end of therapy, particularly when there’s an issue with placement of a patient. If they’re isolated, that can slow down the placement into a long-term care facility, for example."


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.